The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)

This is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage IIICr of cervical cancer have longer PFS and/or OS with lymph node dissection before CCRT when compared to CCRT.

Trial Details

NCT ID
NCT04555226
Phase
NA
Sponsor
Chongqing University Cancer Hospital
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Lymph node dissection
  • Standard chemoradiation±pembrolizumab
  • Chemoradiation± pembrolizumab
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Histopathology: squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma
  • Cervical cancer stage IIICr (confirmed by CT/MRI/PET/CT) and the short diameter of image-positive lymph node ≥15mm
  • ECOG score 0\~1
  • Expected survival over 6 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →